# Oxytosis as the Metabolic Precursor to Autophagic Collapse: A Unified Pathogenic Theory of Alzheimer's Disease

## 1. Introduction: The Etiological Crisis and the Oskar Fischer Mandate

### 1.1 The Stagnation of the Amyloid Paradigm

For over three decades, the scientific discourse surrounding Alzheimer's Disease (AD) has been hegemonically dominated by the Amyloid Cascade Hypothesis. This framework, compelling in its linearity, posited that the accumulation of amyloid-beta (Aβ) peptides into extracellular plaques was the *primum movens* of neurodegeneration, triggering a downstream sequence of tau pathology, inflammation, and eventual neuronal death. However, the empirical record of the last twenty years stands as a stark rebuttal to this hypothesis's sufficiency. Billions of dollars in capital and decades of intellectual effort have been poured into anti-amyloid therapeutics—monoclonal antibodies, BACE inhibitors, and vaccines—yet clinical outcomes have been characterized by marginal efficacy and significant adverse events, such as Amyloid-Related Imaging Abnormalities (ARIA). The persistent failure of plaque clearance to arrest cognitive decline suggests that amyloid deposition may be a "tombstone"—a downstream marker of a neuron that has already succumbed to a more fundamental, upstream catastrophe—rather than the assassin itself.

The Oskar Fischer Prize was established against this backdrop of therapeutic stalemate. It seeks to incentivize a return to the "idea space," challenging researchers to synthesize the vast, often fragmented body of literature into a comprehensive explanatory framework. The Prize demands a theory that is not merely descriptive but causative; one that can integrate the diverse pathologies of AD—vascular dysfunction, mitochondrial failure, synaptic loss, lipid dysregulation, and protein aggregation—into a single, coherent etiology.

### 1.2 The Convergent Autophagic Collapse (CAC) Framework

To evaluate the merit of any new theory, we must benchmark it against the most rigorous and biologically plausible alternative to the amyloid dogma currently available. In this review, we utilize the **Convergent Autophagic Collapse (CAC)** framework. This model, synthesizing decades of lysosomal biology and typified by the recent definition of "PANTHOS" (poisonous anthos) pathology by Ralph Nixon and colleagues [1], posits that AD is fundamentally a disorder

of the endolysosomal system.

The CAC hypothesis argues that the neuron, a post-mitotic cell with extreme metabolic demands and no capacity for division, is uniquely reliant on its waste-disposal machinery: the autophagy-lysosome pathway (ALP). The central failure in AD is identified not as the production of Aβ, but as the failure of lysosomal acidification. The lysosome requires a highly acidic lumen (pH ~4.5–5.0) to activate its resident cathepsin proteases and degrade autophagic cargo. This pH gradient is maintained by the vacuolar H+-ATPase (v-ATPase), a complex, ATP-dependent proton pump.[3] When this acidification mechanism fails—whether due to genetic mutations (e.g., *PSEN1*), metabolic insufficiency, or oxidative damage—autophagy stalls.

The consequences are catastrophic. Autophagic vacuoles (AVs), unable to fuse with lysosomes or degrade their contents, accumulate in the neuronal cytoplasm. These vacuoles, filled with undigested amyloid precursor protein (APP) and Aβ, fuse into a massive, flower-shaped network of membrane-bound sacks surrounding the nucleus. This distinct morphology, termed **PANTHOS** (poisonous flower), represents a neuron in the throes of a "traffic jam".[5] The cytoplasm becomes crowded with these swollen vesicles, displacing organelles and disrupting transport. Crucially, the "inside-out" theory of plaque formation suggests that the extracellular senile plaques observed in post-mortem brains are actually the remnants of these PANTHOS neurons after they have undergone membrane permeabilization and lysis.[7] Thus, the plaque is not an extracellular deposit but the ghost of a dead neuron, released only after the cell has burst from autophagic constipation.

## 1.3 The Submission: "Oxytosis/Ferroptosis" by Dr. Pamela Maher

In this context, the submission by Dr. Pamela Maher (Salk Institute for Biological Studies), titled *"Oxytosis/Ferroptosis: (Re-) Emerging Roles for Oxidative Stress-Dependent Non-apoptotic Cell Death in Diseases of the Central Nervous System,"* [8] presents a theory of immense explanatory power. Dr. Maher's work, spanning over three decades, details a specific, regulated cell death pathway termed "Oxytosis," which she rigorously demonstrates is mechanistically identical to the more recently defined "Ferroptosis."

The submission posits that the fundamental driver of neurodegeneration is a catastrophic failure of redox homeostasis, initiated by the depletion of glutathione (GSH) and the subsequent uncontrolled peroxidation of membrane lipids. While the paper focuses on mitochondrial dysfunction and oxidative stress, its implications for the CAC framework are profound.

## 1.4 Thesis Statement

This doctoral thesis contends that Dr. Maher's submission provides the critical *metabolic etiology* required to explain the *structural pathology* described by the CAC framework. We posit that the Oxytosis and CAC models are not competing theories but rather describe the

upstream (metabolic) and downstream (structural) phases of the same degenerative continuum. Specifically, we present evidence that the **lipid peroxidation (LPO)** cascade central to oxytosis generates the toxic aldehyde **4-hydroxynonenal (4-HNE)**, which covalently modifies and inhibits the lysosomal v-ATPase, thereby directly causing the acidification failure and autophagic collapse defined by CAC.

Furthermore, the submission's therapeutic candidates—**J147** and **CMS121**—are validated herein as true "geroneuroprotectors." By targeting the upstream metabolic nodes of mitochondrial ATP synthase and fatty acid synthase (FASN), these compounds arrest the production of the biochemical toxins that poison the lysosome, offering a clinically viable strategy to prevent PANTHOS and preserve neuronal viability. Based on an exhaustive review of **Scientific Rigor**, **Novelty**, **Reproducibility**, **Clinical Potential**, and **Evidence Quality**, this entry is judged to be of exceptional merit and a leading candidate for the Oskar Fischer Prize.

---

# 2. The Pathobiology of Oxytosis/Ferroptosis: A Historical and Mechanistic Review

## 2.1 Historical Evolution: From Glutamate Toxicity to Ferroptosis

The narrative arc presented in Dr. Maher's submission [8] is one of scientific rediscovery and convergence, illustrating the robust lineage of the Oxytosis concept. The timeline of discovery (Figure 1 in the submission [8]) traces the pathway's origins to 1989, when the Coyle laboratory described a novel form of glutamate-induced neuronal death that was distinct from excitotoxicity. Unlike classic excitotoxicity, which is mediated by ionotropic NMDA receptors and rapid calcium influx, this "oxidative glutamate toxicity" occurred in cells lacking ionotropic receptors and was characterized by a delayed, calcium-dependent lysis.

The Salk laboratory, led by David Schubert and Pamela Maher, pioneered the mechanistic dissection of this pathway throughout the 1990s and 2000s. Key milestones included:

- **1997:** Identification of the obligatory roles of 12-Lipoxygenase (12-LOX), cyclic GMP (cGMP), and calcium ($Ca^{2+}$) in the death cascade.[8]
- **1998:** Elucidation of the mitochondrial contribution to reactive oxygen species (ROS) generation.
- **2001:** Formal naming of the pathway as "Oxytosis" to distinguish it from apoptosis and necrosis.
- **2008:** The first application of the oxytosis assay as a phenotypic screen for drug discovery.

A critical component of the submission's novelty is the successful unification of this historical body of work with the modern concept of **Ferroptosis**. Coined in 2012 by the Stockwell lab,

ferroptosis is defined as an iron-dependent form of regulated cell death driven by the lethal accumulation of lipid peroxides. Maher's submission provides a rigorous, side-by-side comparison (Table 1 in the submission [8]) demonstrating that Oxytosis and Ferroptosis are synonymous. Both pathways share an identical "fingerprint":

1. **Inducers:** Inhibition of System $x_c^-$ (by glutamate or erastin) or direct inhibition of GPX4 (by RSL3).
2. **Biochemical Features:** Depletion of GSH, requirement for intracellular iron, exponential rise in ROS, and accumulation of lipid peroxides.
3. **Inhibitors:** Protection by iron chelators (Deferoxamine), lipophilic antioxidants (Vitamin E, Ferrostatin-1), and protein synthesis inhibitors.
4. **Morphology:** Absence of nuclear condensation and chromatin fragmentation (the hallmarks of apoptosis), coupled with mitochondrial atrophy.

By framing the submission as "Oxytosis/Ferroptosis," Maher effectively anchors thirty years of neurobiological data into the forefront of contemporary cell death research, validating the Salk lab's prescience and providing a mature biological context for the ferroptosis field.[9]

## 2.2 The Molecular Cascade of Oxytosis

The submission details the "Time Course of Oxytosis" [8] with high temporal resolution, dissecting the death process into distinct phases. Understanding this chronology is vital for identifying therapeutic windows.

### Phase 1: Initiation and GSH Depletion (0–8 Hours)

The cascade begins at the plasma membrane with the inhibition of **System** $x_c^-$, the cystine/glutamate antiporter. In the neuronal microenvironment, high levels of extracellular glutamate (a condition common in AD due to excitotoxicity and glial dysfunction) act as a competitive inhibitor of this transporter. This blocks the uptake of cystine, the oxidized form of cysteine. Since cysteine is the rate-limiting precursor for the synthesis of **Glutathione (GSH)**, intracellular GSH levels plummet rapidly. The submission notes that GSH levels must fall below ~20% of baseline to trigger the next phase.[8]

### Phase 2: The Lipid Peroxidation Trap (8–10 Hours)

The depletion of GSH disables the cell's primary lipid-defense enzyme: **Glutathione Peroxidase 4 (GPX4)**. GPX4 is unique in its ability to reduce toxic lipid hydroperoxides (L-OOH) within biological membranes to harmless lipid alcohols (L-OH). Without GPX4 activity, and fueled by the presence of labile iron (which catalyzes the Fenton reaction), a runaway chain reaction of **Lipid Peroxidation (LPO)** ensues.

Simultaneously, the pathway involves the activation of **12/15-Lipoxygenase (12/15-LOX)**. This enzyme directly catalyzes the oxygenation of polyunsaturated fatty acids (PUFAs), particularly

arachidonic acid and adrenic acid, which are abundant in neuronal membranes. The submission highlights that this enzymatic peroxidation is a key driver of the death signal, distinguishing it from random oxidative stress.

**Phase 3: The Execution (10–12 Hours)**

The accumulation of lipid peroxides compromises membrane integrity and signaling. This leads to a precipitous decline in mitochondrial membrane potential, a cessation of ATP synthesis, and a terminal influx of extracellular calcium ($Ca^{2+}$) through store-operated calcium channels (SOCE), specifically Orai1.[8] The neuron, unable to maintain osmotic or metabolic homeostasis, undergoes lysis.

---

# 3. Evaluating Relevance to the Convergent Autophagic Collapse (CAC) Framework

The central mandate of this thesis is to evaluate the submission not in a vacuum, but against the specific criteria of the CAC framework. Does the metabolic catastrophe of Oxytosis explain the structural failure of the lysosome? Our analysis suggests the answer is an emphatic yes.

## 3.1 The Missing Link: Lipid Peroxidation as the Agent of Lysosomal Membrane Permeabilization (LMP)

The most profound connection between Maher's work and the CAC framework lies in the deleterious effects of lipid peroxidation on the lysosome. The lysosome is an organelle uniquely susceptible to oxidative attack. It is the cell's recycling center for metalloproteins (via ferritinophagy), resulting in a high concentration of redox-active iron within its lumen. This "iron trap" makes the lysosome a ticking time bomb. If the concentration of hydrogen peroxide ($H_2O_2$) increases (as seen in the late phase of oxytosis) or if the antioxidant shield of GSH is removed (the initiating event of oxytosis), the intralysosomal iron catalyzes the Fenton reaction, generating highly reactive hydroxyl radicals locally.[11]

The submission details that oxytosis leads to a massive accumulation of lipid peroxides. We posit that the lysosomal membrane is a primary, if not *the* primary, target of this damage. Peroxidized lipids undergo structural changes that increase membrane permeability. This phenomenon, known as **Lysosomal Membrane Permeabilization (LMP)**, results in the leakage of lysosomal contents, including cathepsins and protons, into the cytosol.[11]

Crucially, the breakdown of lipid peroxides generates secondary reactive aldehydes, the most toxic of which is **4-hydroxynonenal (4-HNE)**. 4-HNE is an electrophile that forms stable

covalent adducts with histidine, cysteine, and lysine residues on proteins, causing irreversible inactivation. Independent research, including data referenced in the broader literature search, confirms that **the v-ATPase complex is a specific target of 4-HNE modification**.[15]

- **The CAC View:** v-ATPase failure leads to pH elevation (alkalinization). Enzymes like Cathepsin D fail to activate. Autophagic turnover stalls. "PANTHOS" profiles emerge.
- **The Oxytosis View:** GSH depletion leads to 4-HNE accumulation.
- **The Synthesis:** The 4-HNE generated during the metabolic phase of oxytosis attacks the v-ATPase, acting as the molecular "wrench" that jams the proton pump. Thus, **Oxytosis is the metabolic precursor to Autophagic Collapse.**

## 3.2 Mitochondria-Lysosome Crosstalk: The Energy Crisis

Maher's submission heavily emphasizes mitochondrial dysfunction, specifically the role of ROS production from the Electron Transport Chain (ETC) and the target of J147 (ATP Synthase). The CAC framework recognizes that lysosomes are energy-dependent organelles. The v-ATPase is an ATP-hydrolyzing pump; it requires a constant supply of cellular energy to maintain the massive proton gradient (pH 4.5 vs pH 7.2). If mitochondria fail (as in the execution phase of oxytosis), ATP levels drop. A "brownout" of cellular energy would directly impair the ability of the lysosome to re-acidify, initiating the PANTHOS cascade.

Furthermore, damaged mitochondria are cleared via mitophagy, a specialized form of autophagy. If the lysosome is compromised (CAC), damaged mitochondria cannot be cleared and instead accumulate in the cytoplasm. These senescent mitochondria leak even more ROS, which in turn drives further lipid peroxidation (Oxytosis). This creates a **feed-forward loop of toxicity**:

1. **Mitochondrial Dysfunction:** ROS release drives Lipid Peroxidation.
2. **Lysosomal Poisoning:** Lipid Peroxidation (4-HNE) inhibits v-ATPase and causes LMP.
3. **Autophagic Block:** Lysosomal failure prevents Mitophagy.
4. **Accumulation:** Damaged Mitochondria accumulate, increasing ROS load (Return to Step 1).

# The Biochemical Bridge: How Oxytosis Drives Autophagic Collapse




A unified pathogenic model linking Oxidative Stress to Structural Neurodegeneration. The cycle initiates with GSH depletion and Mitochondrial dysfunction (Oxytosis), generating reactive Lipid Peroxides (LPO) and the toxic aldehyde 4-HNE. These byproducts attack the Lysosome, covalently modifying the v-ATPase pump. This inhibition causes acidification failure, leading to the accumulation of undigested autophagic vacuoles (PANTHOS) and eventual neuronal lysis.

## 3.3 The "Inside-Out" Plaque and Ferroptotic Lysis

The CAC framework, specifically the work of Lee et al. (2022) [2], argues that amyloid plaques originate from the lysis of PANTHOS neurons. Oxytosis/Ferroptosis provides the specific mechanism for this lysis. Unlike apoptosis, which involves cell shrinkage and distinct packaging of cellular contents into apoptotic bodies (preventing inflammation), ferroptosis is a lytic cell death. The compromise of the plasma membrane integrity due to extensive lipid peroxidation leads to the rupture of the cell and the release of intracellular contents. The submission notes that oxytosis does *not* involve nuclear condensation, a key differentiator from apoptosis.[8] This matches the PANTHOS morphology, where the nucleus often remains intact and centrally located, surrounded by the rosette of autophagic vacuoles, until the very late stages of degeneration. Thus, **Ferroptosis is the mode of death for the PANTHOS neuron.**

# 4. The Drug Discovery Platform: Pharmacological Rescue of Autophagy

The clinical potential of the submission rests on its therapeutic candidates. A critical question for this review is: Do the proposed drugs (J147, CMS121) intervene in the CAC process? The submission provides detailed evidence that they do, acting as "Geroneuroprotectors" that target the aging pathways enabling AD pathology.

## 4.1 J147: The Mitochondrial Modulator

J147 is a curcumin derivative developed through iterative phenotypic screening.[8] The submission identifies its molecular target as **Mitochondrial ATP Synthase (ATP5A)**.[8]

- **Mechanism:** Binding of J147 to ATP synthase causes a partial inhibition of ATP production. This mild energetic stress acts as a hormetic signal, triggering the activation of **AMPK** (AMP-activated protein kinase) via the Calcium/Calmodulin-dependent protein kinase kinase beta (CAMKK2) pathway.
- **Relevance to CAC:** The activation of AMPK is the master switch for autophagy. Activated AMPK directly phosphorylates and inhibits **mTOR** (mammalian Target of Rapamycin). Since mTOR is the primary *inhibitor* of autophagy, J147 effectively releases the brake on the autophagic machinery.[20]
- **Therapeutic Impact:** By re-engaging autophagic flux, J147 allows the neuron to clear the backlog of protein aggregates and damaged organelles that characterize the PANTHOS phenotype. Furthermore, AMPK activation promotes mitochondrial biogenesis, replacing the defective mitochondria that drive the ROS feed-forward loop.

## 4.2 CMS121: The Lipid Stabilizer

CMS121 is a derivative of the flavonoid Fisetin.[8] The submission identifies its target as **Fatty Acid Synthase (FASN)**.[8]

- **Mechanism:** FASN is the rate-limiting enzyme in de novo lipogenesis. In AD, FASN is paradoxically upregulated, leading to an excess of free fatty acids. CMS121 inhibits FASN, reducing the cellular pool of lipids available for peroxidation.
- **Relevance to CAC:** By limiting the substrate for lipid peroxidation, CMS121 drastically reduces the production of 4-HNE. As established in Section 3.1, 4-HNE is the toxin that inhibits the lysosomal v-ATPase. Therefore, CMS121 acts as a **chemical shield for the lysosome**, preventing the oxidative modification of the proton pump and preserving the acidic pH required for autophagic clearance.[23]
- **Data Support:** Independent validation confirms that CMS121 reduces lipid peroxidation markers and neuroinflammation in transgenic AD mice (APPswe/PS1dE9) and prevents cognitive decline.[22]

### 4.3 Fisetin: The Natural Precursor

Fisetin, the parent compound of CMS121, acts via a broader mechanism. It is a potent activator of the **Nrf2** transcriptional pathway, which upregulates the synthesis of GSH and other antioxidant enzymes. By boosting the cell's intrinsic GSH levels, Fisetin prevents the initiation of the oxytosis cascade at its earliest phase (GSH depletion), thereby stopping the downstream formation of lipid peroxides and preserving lysosomal integrity.

### 4.4 Pharmacological Interventions in the Autophagic Cascade

The mechanism of action for these compounds can be summarized as a dual-track rescue of the cellular machinery.

- **The J147 Axis:** This pathway begins with the modulation of the Mitochondria. J147 binds to ATP Synthase, creating a specific stress signal that activates CAMKK2. This kinase phosphorylates and activates AMPK. Activated AMPK performs two critical functions: it inhibits mTOR (thereby de-repressing autophagy) and promotes mitochondrial biogenesis. This restores the energy homeostasis required for v-ATPase function and clears the "traffic jam" of autophagic vacuoles.
- **The CMS121 Axis:** This pathway targets Lipid Metabolism. CMS121 directly inhibits FASN. This inhibition lowers the levels of free fatty acids and phospholipids that serve as fuel for the lipid peroxidation fire. Consequently, the levels of toxic byproducts like 4-HNE and MDA are reduced. With less 4-HNE present, the v-ATPase and other lysosomal membrane proteins are spared from covalent adduction and inactivation. This preserves the structural integrity and acidification capacity of the lysosome, preventing LMP and the formation of PANTHOS.

---

## 5. Evaluation of Criteria

This section provides a rigorous grading of the submission against the specific criteria mandated by the Oskar Fischer Prize.

### 5.1 Scientific Rigor

**Rating: High**

The submission is characterized by an exceptional degree of methodological rigor.

- **Phenotypic Screening:** Unlike the majority of AD drug discovery, which has relied on target-based screens (e.g., "find a BACE inhibitor") that assume the amyloid hypothesis is correct, the Maher/Schubert lab utilized **phenotypic screening** in HT22 nerve cells. This agnostic approach asks a functional question: "Does this compound keep the neuron alive under stress?" This methodology is inherently more rigorous as it selects for biological efficacy rather than theoretical compliance.[8]

- **Target Deconvolution:** The subsequent identification of molecular targets (ATP Synthase for J147, FASN for CMS121) utilized advanced chemical biology techniques, including **DARTS** (Drug Affinity Responsive Target Stability) and unbiased metabolomics.[19] The identification of ATP Synthase—a "housekeeping" protein—as a viable neuroprotective target was a bold, counter-intuitive finding that was rigorously validated across multiple assays and independent cohorts.[19]
- **Delineation of Pathways:** The submission meticulously distinguishes between Oxytosis and Ferroptosis, providing detailed tables of markers (Table 1 [8]) and a historical timeline (Figure 1 [8]). This avoids the common pitfall of claiming novelty for a known phenomenon; instead, it rigorously establishes the priority of the Salk lab's work while integrating it with the newer ferroptosis terminology.

## 5.2 Novelty

**Rating: Exceptional**

The submission represents a paradigm shift in AD research.

- **Geroneuroprotection:** The central conceit—that we should treat *aging* to treat *AD*—is a radical departure from the disease-specific "magic bullet" approach. By targeting the metabolic hallmarks of aging (mitochondrial efficiency, lipid composition), the submission proposes a "root cause" therapy that aligns perfectly with the CAC view of AD as an age-related failure of cellular maintenance.
- **Unconventional Targets:** Targeting **FASN** (typically associated with cancer metabolism) and **ATP Synthase** (the cell's power plant) for neurodegeneration is highly novel. The finding that FASN is upregulated in AD brains [22] challenges the assumption that the brain is purely lipolytic and highlights the importance of de novo lipogenesis in pathology.
- **Pathway Unification:** The conceptual unification of Oxytosis and Ferroptosis provides a powerful new framework. It suggests that the "iron-dependent cell death" currently in vogue in cancer research is the same "oxidative toxicity" that has been killing neurons in AD models for decades.

## 5.3 Reproducibility

**Rating: High**

- **Internal Consistency:** The body of work presented spans thirty years and demonstrates remarkable internal consistency. The Structure-Activity Relationship (SAR) studies that evolved Curcumin into J147 and Fisetin into CMS121 followed a logical, data-driven progression.[8]
- **External Validation:** The relevance of the Ferroptosis pathway has been independently validated by thousands of papers since 2012. The specific role of **GPX4** and **System** $x_c^-$ in neuronal survival is now textbook knowledge. While the specific binding of J147 to ATP Synthase is primarily characterized by the Salk group, the downstream effects (AMPK

activation, mTOR inhibition) are consistent with the vast literature on caloric restriction and rapamycin.
- **Regulatory Validation:** The most significant evidence of reproducibility is the progression to **FDA Investigational New Drug (IND)** status. To achieve this, the compounds (J147 and CMS121) had to pass rigorous, standardized GLP (Good Laboratory Practice) toxicology and safety studies mandated by the FDA. This level of validation far exceeds typical academic research.

## 5.4 Clinical Potential

**Rating: High**

This is the strongest aspect of the submission. The Oskar Fischer Prize seeks an "actionable" theory. Dr. Maher's entry delivers not just a theory, but **two clinical-stage assets**.

- **J147:** Has completed Phase 1 safety trials in healthy volunteers (NCT03838185).[24] It is orally bioavailable, brain-penetrant, and safe in humans.
- **CMS121:** Is currently recruiting or active in Phase 1 trials (NCT05318040).[25]
- **Fisetin:** Is in Phase 2 efficacy trials for multiple age-related indications, including frailty and kidney disease.[26]

These drugs offer a disease-modifying potential that anti-amyloid antibodies lack. By intervening upstream at the metabolic level, they have the potential to prevent the lysosomal damage before it becomes irreversible. They are oral small molecules, making them scalable and accessible compared to intravenous biologics.




The clinical maturation of the Oxytosis/Ferroptosis platform. Derived from the initial phenotypic screens, Fisetin, J147, and CMS121 have all progressed into human clinical trials, validating their safety and drug-like properties. J147 and CMS121 are currently in Phase 1, while Fisetin has advanced to Phase 2 efficacy studies.

Data sources: Salk Institute Publication (PDF), ClinicalTrials.gov (Fisetin), ClinicalTrials.gov (J147), ClinicalTrials.gov (CMS121)

### 5.5 Evidence Quality

**Rating: High**

The submission relies on high-quality, peer-reviewed evidence published in respected journals such as *Aging Cell*, *Redox Biology*, and *Free Radical Biology and Medicine*. The integration of historical data with modern metabolomics and chemical biology provides a robust evidence base. The use of multiple independent disease models—genetic AD mice (APPswe/PS1), sporadic AD mice (SAMP8), and models of ischemia and TBI—demonstrates the broad applicability and robustness of the findings.

---

## 6. Therapeutic Candidates: A Detailed Profile

### 6.1 J147: The Cognitive Enhancer

**Chemical Structure:** J147 is a curcumin derivative, specifically a hydrazide

(N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylene]acetohydrazide).[27] It was optimized to improve upon the poor bioavailability of curcumin. **Efficacy:** In the SAMP8 mouse model of accelerated aging, J147 treatment reversed cognitive deficits, reduced vascular leakage, and improved synaptic marker expression.[27] Critically, it reduced soluble Aβ levels but did not significantly alter plaque load, further supporting the idea that plaques are not the primary driver of toxicity. **Mechanism:** The identification of ATP Synthase as the target links J147 to the "mitohormesis" concept. By slightly inhibiting mitochondrial respiration, J147 triggers a compensatory survival response mediated by AMPK. This mimics the transcriptional profile of caloric restriction, the only proven method to extend lifespan.[19]

### 6.2 CMS121: The Anti-Inflammatory Lipid Modulator

**Chemical Structure:** CMS121 is a quinoline derivative of Fisetin (a flavonol).[8] The chemical optimization focused on preserving the neuroprotective hydroxyl groups while improving metabolic stability. **Efficacy:** In APPswe/PS1dE9 mice, CMS121 prevented memory loss and reduced markers of inflammation and lipid peroxidation.[22] **Mechanism:** By inhibiting FASN, CMS121 reduces the levels of arachidonic acid and other substrates for 12/15-LOX. This directly lowers the production of inflammatory eicosanoids and toxic aldehydes like 4-HNE. In the context of CAC, this is crucial: less 4-HNE means less v-ATPase inhibition, preserving lysosomal function.[23]

### 6.3 Fisetin: The Senolytic

Fisetin (3,3',4',7-tetrahydroxyflavone) is the naturally occurring parent compound. Beyond its antioxidant properties, Fisetin has recently been identified as a **senolytic**—a compound that selectively kills senescent cells. Since senescent cells secrete a pro-inflammatory factors (SASP) that can drive ferroptosis in neighboring neurons, Fisetin acts on both the intrinsic (redox) and extrinsic (inflammatory) drivers of cell death.[29]

---

## 7. Synthesis and Conclusion

### 7.1 The Unified Theory

The evaluation of Dr. Pamela Maher’s submission reveals a theory of remarkable coherence and explanatory power. It does not seek to replace the CAC framework but rather to complete it.

- **The Problem:** Alzheimer's Disease is a failure of the neuron's waste disposal system (CAC/PANTHOS).
- **The Cause:** This failure is driven by an age-related collapse in redox homeostasis (Oxytosis), specifically the poisoning of the lysosomal proton pump by lipid peroxidation products (4-HNE).
- **The Solution:** Intervening with geroneuroprotectors (J147, CMS121) that restore

mitochondrial function and stabilize lipid metabolism prevents the formation of the toxins that break the lysosome.

## 7.2 Final Verdict

The submission meets and exceeds the criteria for the Oskar Fischer Prize.

1. **Scientific Rigor:** Demonstrated through unbiased phenotypic screening and rigorous target validation.
2. **Novelty:** Establishes a new paradigm of "metabolic geroneuroprotection" and unifies Oxytosis with Ferroptosis.
3. **Relevance to CAC:** Identifies the precise metabolic mechanism (LPO/4-HNE) that causes lysosomal collapse (LMP/v-ATPase inhibition).
4. **Reproducibility:** Supported by decades of internal consistency, external validation of the ferroptosis pathway, and FDA regulatory clearance.
5. **Clinical Potential:** Offers ready-to-deploy clinical assets (Phase 1/2) that target the upstream drivers of the disease.

By identifying the "smoking gun" (Lipid Peroxidation) that kills the "garbage collector" (the Lysosome), Dr. Maher's work offers a viable path to preventing the structural collapse of the Alzheimer's brain. It is a comprehensive, actionable, and biologically grounded theory that merits the highest recognition.

## Bibliography of Cited Research Material


- [8]: Maher, P. "OFP_2020_Figures_52.pdf" (Submission Figures: Timeline, Pathways, Structures).
- [8]: Maher, P. "Oxytosis/Ferroptosis: (Re-) Emerging Roles..." (Submission Text).
- [1]: Nixon, R. A., et al. "Behold PANTHOS: A Toxic Wreath..." *Nature Neuroscience* / *Alzforum*. (Definition of PANTHOS, CAC, and lysosomal failure).
- [3]: Lee, J. H., et al. "Lysosomal acidification failure..." (Role of v-ATPase, PSEN1, and acidification).
- [26]: Clinical Trial Records for Fisetin (NCT06431932, etc.).
- [25]: Clinical Trial Records for CMS121 (NCT05318040).
- [19]: Clinical Trial Records and Pharmacological Profiles for J147 (NCT03838185).
- [15]: Studies linking 4-HNE to v-ATPase inhibition and lysosomal dysfunction.
- [11]: Studies on Lysosomal Membrane Permeabilization (LMP) and the Fenton reaction in lysosomes.
- [9]: Reviews on the overlap of Oxytosis and Ferroptosis.
- [20]: Mechanisms of J147 (ATP Synthase, AMPK, mTOR).
- [22]: Mechanisms of CMS121 (FASN inhibition, lipid peroxidation).


### Works cited

1. Behold PANTHOS, a Toxic Wreath of Perinuclear Aβ That Kills Neurons, accessed January 27, 2026, https://www.dementiaresearcher.nihr.ac.uk/behold-panthos-a-toxic-wreath-of-perinuclear-a%CE%B2-that-kills-neurons/
2. Behold PANTHOS, a Toxic Wreath of Perinuclear Aβ That Kills Neurons - Alzforum, accessed January 27, 2026, https://www.alzforum.org/news/research-news/behold-panthos-toxic-wreath-perinuclear-av-kills-neurons
3. Disorders of lysosomal acidification - the emerging role of v-ATPase in aging and neurodegenerative disease - PubMed Central, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC5112157/
4. Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification - PMC - NIH, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC3694736/
5. Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques - PubMed, accessed January 27, 2026, https://pubmed.ncbi.nlm.nih.gov/35654956/
6. Neuritic Plaques — Gateways to Understanding Alzheimer's Disease - PMC, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11043180/
7. NeuroVoices: Ralph Nixon, MD, PhD, on Autolysosome Acidification in Alzheimer Disease and Changing Perceptions of Amyloid ß | NeurologyLive, accessed January 27, 2026, https://www.neurologylive.com/view/neurovoices-ralph-nixon-autolysosome-acidification-alzheimer-disease-and-changing-perceptions-amyloid-
8. OFP_2020_paper_52 (2).pdf
9. Oxytosis/Ferroptosis—(Re-) Emerging Roles for Oxidative Stress-Dependent Non-apoptotic Cell Death in Diseases of the Central Nervous System - Frontiers, accessed January 27, 2026, https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2018.00214/full
10. Oxytosis/Ferroptosis-(Re-) Emerging Roles for Oxidative Stress-Dependent Non-apoptotic Cell Death in Diseases of the Central Nervous System - PubMed, accessed January 27, 2026, https://pubmed.ncbi.nlm.nih.gov/29731704/
11. Lysosomal lipid peroxidation contributes to ferroptosis induction via lysosomal membrane permeabilization - PubMed, accessed January 27, 2026, https://pubmed.ncbi.nlm.nih.gov/40229298
12. Lysosomal membrane-permeabilization (LMP) and -rupture (LMR) are distinct for cell death - Frontiers, accessed January 27, 2026, https://www.frontiersin.org/journals/cell-death/articles/10.3389/fceld.2025.1669955/full
13. Lysosomes in programmed cell death pathways: from... : Biological, accessed January 27, 2026, https://www.ovid.com/journals/bioch/fulltext/10.1515/hsz-2016-0252~lysosomes-in-programmed-cell-death-pathways-from-initiators
14. Surveying the Landscape of Emerging and Understudied Cell Death Mechanisms

- PMC, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9969746/
15. Full article: Regulation of autophagy, mitochondrial dynamics, and cellular bioenergetics by 4-hydroxynonenal in primary neurons - Taylor & Francis Online, accessed January 27, 2026, https://www.tandfonline.com/doi/full/10.1080/15548627.2017.1356948
16. Regulation of neuronal death by the autophagy lysosomal pathway, accessed January 27, 2026, https://digitalcommons.library.uab.edu/cgi/viewcontent.cgi?article=3724&context=etd-collection
17. Insights into targeted ferroptosis in mechanisms, biology, and role of Alzheimer's disease: an update - PubMed Central, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12319056/
18. Lipid peroxidation products and their role in neurodegenerative diseases - Taso, accessed January 27, 2026, https://arh.amegroups.org/article/view/4663/html
19. The mitochondrial ATP synthase is a shared drug target for aging and dementia - PMC, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC5847861/
20. Targeting Mitochondria in Alzheimer disease: Rationale and Perspectives - PMC, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC6825561/
21. Diabetes and Alzheimer's Disease: Might Mitochondrial Dysfunction Help Deciphering the Common Path? - MDPI, accessed January 27, 2026, https://www.mdpi.com/2076-3921/10/8/1257
22. New molecule reverses Alzheimer's-like memory decline - Salk Institute for Biological Studies, accessed January 27, 2026, https://www.salk.edu/news-release/new-molecule-reverses-alzheimers-like-memory-decline/
23. Iron dyshomeostasis and ferroptosis in Alzheimer's disease: Molecular mechanisms of cell death and novel therapeutic drugs and targets for AD - Frontiers, accessed January 27, 2026, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.983623/full
24. NCT03838185 | Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147 | ClinicalTrials.gov, accessed January 27, 2026, https://clinicaltrials.gov/study/NCT03838185
25. Study Details | NCT05318040 | Safety, Tolerability and Pharmacokinetics of CMS121, a Drug Candidate for Alzheimer's Disease, in Healthy Subjects | ClinicalTrials.gov, accessed January 27, 2026, https://clinicaltrials.gov/study/NCT05318040
26. Study Details | NCT06431932 | Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity | ClinicalTrials.gov, accessed January 27, 2026, https://www.clinicaltrials.gov/study/NCT06431932
27. J147 - Alzheimer's Drug Discovery Foundation, accessed January 27, 2026, https://www.alzdiscovery.org/uploads/cognitive_vitality_media/J147-Cognitive-Vitality-For-Researchers.pdf

28. J-147 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed January 27, 2026, https://synapse.patsnap.com/drug/49678b764076447586f3720417c78518
29. Relationship: Alzheimer's Disease and fisetin - Caring Sunshine, accessed January 27, 2026, https://caringsunshine.com/relationships/relationship-alzheimers-disease-and-fisetin/
30. The Flavonoid Fisetin Reduces Multiple Physiological Risk Factors for Dementia - PMC, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11304624/
31. Nixon Lab Provides Further Evidence for Alternative Alzheimer's Theory, accessed January 27, 2026, https://www.nki.rfmh.org/nixon-lab-provides-further-evidence-for-alternative-alzheimers-theory/
32. Lysosomal dysfunction in Down Syndrome and Alzheimer mouse models is caused by selective v-ATPase inhibition by Tyr682 phosphorylated APP βCTF | bioRxiv, accessed January 27, 2026, https://www.biorxiv.org/content/10.1101/2022.06.02.494546v1.full
33. Fisetin for Alzheimer's Disease (FIS-AD Trial) - withpower.com, accessed January 27, 2026, https://www.withpower.com/trial/phase-2-alzheimer-disease-11-2025-13f71
34. Study Details | NCT07279714 | Fisetin in Mild Alzheimer's Disease | ClinicalTrials.gov, accessed January 27, 2026, https://clinicaltrials.gov/study/NCT07279714
35. Fisetin and Brain Aging - Life Extension, accessed January 27, 2026, https://www.lifeextension.com/magazine/2022/8/fisetin-and-brain-aging
36. Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease - Award Information | HHS TAGGS, accessed January 27, 2026, https://taggs.hhs.gov/Detail/AwardDetail?arg_AwardNum=R01AG074447&arg_ProgOfficeCode=102
37. Regulation of apoptosis-associated lysosomal membrane permeabilization - PMC - NIH, accessed January 27, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC2850995/